All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
No Abstract BioWorld International CorrespondentMovetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.With a European product launch imminent, the company offers a far less risky proposition than most, however.